症状性孤立性浅静脉血栓形成患者的临床病程:ICARO随访研究
ICARO随访研究观察411例急性症状性孤立性浅静脉血栓形成(iSVT)门诊患者,中位随访1026天。52例(12.9%)发生症状性深静脉血栓或肺栓塞,抗凝治疗期间年化率1.3%,停抗凝后4.4%。男性(调整HR 2.03)和活动性实体癌(调整HR 3.14)与未来DVT/PE相关;无癌症患者死亡风险似乎可忽略。
要点
- 停抗凝后DVT/PE年化率4.4%,抗凝治疗期间为1.3%。
- 男性(调整HR 2.03)和活动性实体癌(调整HR 3.14)与未来DVT/PE相关。
- 无癌症患者死亡风险似乎可忽略。
核心结论
- 急性iSVT停抗凝后远期DVT/PE风险具有临床意义,尤其在男性和活动性癌症患者中。
- 无癌症患者死亡风险似乎可忽略。
研究设计与样本
- 观察性多中心研究,收集411例连续门诊急性、症状性、客观诊断的iSVT患者纵向数据,这些患者此前纳入横断面ICARO研究。
- 排除随访<30天的4例和合并DVT或PE的79例后进行分析。
- 主要结局为症状性DVT或PE,安全性结局为大出血和全因死亡。
主要发现
- 中位随访1026天(四分位距610-1796)。
- 52例(12.9%)发生症状性DVT/PE,抗凝治疗期间年化率1.3%(95%CI 0.3-3.9%),停抗凝治疗期间年化率4.4%(95%CI 3.2-5.8%)。
- 男性(调整HR 2.03 [95%CI 1.16-3.54])和活动性实体癌(调整HR 3.14 [95%CI 1.11-8.93])与未来DVT/PE相关;既往DVT/PE未显示显著性,很可能因长期抗凝治疗所致偏倚。
- 治疗期间发生3例大出血,年化率1.4%(95%CI 0.3-4.0%)。
- 16例死亡(年化率1.1% [95%CI 0.6-1.7%]),死因为癌症(n=8)、PE(n=1)、心血管事件(n=3)或其他原因(n=4)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Late sequelae of isolated superficial vein thrombosis (iSVT) have rarely been investigated. We studied 411 consecutive outpatients with acute iSVT with a median follow-up of three years. Male sex and cancer are risk factors for future deep vein thrombosis or pulmonary embolism. Patients without cancer appear to be at a negligible risk for death. SUMMARY: Background Studies of long-term thromboembolic complications and death following acute isolated superficial vein thrombosis (iSVT) of the lower extremities are scarce. Objectives To investigate the course of iSVT in the setting of an observational multicenter study. Methods We collected longitudinal data of 411 consecutive outpatients with acute, symptomatic, objectively diagnosed iSVT who were previously included in the cross-sectional ICARO study. Four patients followed for < 30 days and 79 with concomitant deep vein thrombosis (DVT) or pulmonary embolism (PE) were excluded from the present analysis. The primary outcome was symptomatic DVT or PE. The safety outcomes were major bleeding and all-cause death. Results The median follow-up time was 1026 days (interquartile range 610-1796). Symptomatic DVT/PE occurred in 52 (12.9%) patients, giving annualized rates of 1.3% (95% confidence interval [CI] 0.3-3.9%) on anticoagulant treatment and 4.4% (95% CI 3.2-5.8%) off anticoagulant treatment. Male sex (adjusted hazard ratio [HR] 2.03 [95% CI 1.16-3.54]) and active solid cancer (adjusted HR 3.14 [95% CI 1.11-8.93]) were associated with future DVT/PE, whereas prior DVT/PE failed to show significance, most likely because of bias resulting from prolonged anticoagulant treatment. Three major bleeding events occurred on treatment, giving an annualized rate of 1.4% (95 CI 0.3-4.0%). Death was recorded in 16 patients (annualized rate: 1.1% [95% CI 0.6-1.7%]), and was attributable to cancer (n = 8), PE (n = 1), cardiovascular events (n = 3), or other causes (n = 4). Conclusions The long-term risk of DVT/PE after anticoagulant discontinuation for acute iSVT is clinically relevant, especially in males and in the presence of active cancer. The risk of death appears to be negligible in patients without cancer.
引用
- Barco S, Pomero F, Di Minno MND, et al. Clinical course of patients with symptomatic isolated superficial vein thrombosis: the ICARO follow-up study. J Thromb Haemost. 2017. PMID: 28871623. doi:10.1111/jth.13840
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。